Wotz goin’ on in Canada? And wotz “True Nth”?

So apparently Prostate Cancer Canada has been working (rather secretively) on a series of projects under the umbrella name of their “True Nth” initiative. But it’s a little difficult to work out quite what is encompassed by this initiative, which has been funded (at least in part) by Movember. … READ MORE …

CTFPHC rejects widespread screening for risk of prostate cancer

The Canadian Task Force on Preventive Health Care (CTFPHC) has just issued a guidance document that is not going to make most prostate cancer survivors very happy (either in Canada or elsewhere). … READ MORE …

Health Canada expands clinical indications for use of Zytiga in mCRPC

According to a media release issued by Janssen, Inc. (a division of Johnson & Johnson) earlier today, Health Canada has approved the use of abiraterone acetate (Zytiga®) + prednisone for the treatment of chemotherapy-naive patients with asymptomatic or mildly symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).

Health Canada approves abiraterone acetate (Zytiga)

According to a media release issued by Johnson & Johnson late last week, after a priority review, Health Canada has approved abiraterone acetate (Zytiga™) in combination with prednisone for the treatment of men with metastatic, castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.

Projected “dramatic” increase in diagnosis of prostate cancer in Canada

A new report has suggested that there will be a 201 percent increase in the annual number of prostate cancer diagnoses in Canada between 2009 and 2021. … READ MORE …

The long-term costs of managing prostate cancer

We now know how much it cost the Province of Ontario, in Canada, on average, to manage prostate cancer cases between 1995 and 2002. However, it is doubtful that these data would necessarily be applicable to the same time period in the USA or other nations. … READ MORE …

Prostate cancer news reports: Saturday, July 25, 2009

Today’s news reports address items on:

  • The burden of prostate cancer in Canada
  • Pelvic lymph node dissection and RALP
  • Data from early trials of sipuleucel-T in advanced prostate cancer
  • Implementation of osteoporosis screening guidelines in prostate cancer patients … READ MORE …

Your prostate cancer news update: Saturday, August 16

There is in fact a good deal of news this weekend. Information about four items are provided below and we will discuss additional news items tomorrow. Items in this article include:

  • The relative views of Canadian urologists and radiation oncologists toward PSA screening and treatments for localized disease
  • A complex form of investigational immunotherapy for localized prostate cancer
  • Data suggesting the possibility of a survival benefit resulting from treatment of  hormone refractory prostate cancer patients with docetaxel (Taxotere) + ASA404 (an investigational drug)
  • A new review of psychosocial issues and their impact on management of prostate cancer … READ MORE …